152 related articles for article (PubMed ID: 17431617)
21. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
22. pVAX1 plasmid vector-mediated gene transfer of soluble TRAIL suppresses human hepatocellular carcinoma growth in nude mice.
Zhang Y; Ma CH; Liu H; Zhang XM; Sun WS
Acta Biochim Pol; 2007; 54(2):307-13. PubMed ID: 17546204
[TBL] [Abstract][Full Text] [Related]
23. Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity.
Siegall CB; Liggitt D; Chace D; Tepper MA; Fell HP
Proc Natl Acad Sci U S A; 1994 Sep; 91(20):9514-8. PubMed ID: 7937798
[TBL] [Abstract][Full Text] [Related]
24. [Nanoparticle-mediated endostatin gene therapy targeting hepatocellular carcinoma utilizing heat-inducible promoter].
Zhou JJ; Chen RF; Li ZH; Zhou QB; Tang QB; He XY; Lu HW; Guo N
Zhonghua Yi Xue Za Zhi; 2009 Mar; 89(12):795-9. PubMed ID: 19595115
[TBL] [Abstract][Full Text] [Related]
25. Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs.
Siegall CB; Liggitt D; Chace D; Mixan B; Sugai J; Davidson T; Steinitz M
Clin Cancer Res; 1997 Mar; 3(3):339-45. PubMed ID: 9815690
[TBL] [Abstract][Full Text] [Related]
26. Potent antitumor effect of TRAIL mediated by a novel adeno-associated viral vector targeting to telomerase activity for human hepatocellular carcinoma.
Wang Y; Huang F; Cai H; Zhong S; Liu X; Tan WS
J Gene Med; 2008 May; 10(5):518-26. PubMed ID: 18338833
[TBL] [Abstract][Full Text] [Related]
27. Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen.
Alvarez-Rueda N; Leprieur S; Clémenceau B; Supiot S; Sébille-Rivain V; Faivre-Chauvet A; Davodeau F; Paris F; Barbet J; Aubry J; Birklé S
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5613s-5620s. PubMed ID: 17875797
[TBL] [Abstract][Full Text] [Related]
28. AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice.
Zhang Y; Ma H; Zhang J; Liu S; Liu Y; Zheng D
Life Sci; 2008 Jun; 82(23-24):1154-61. PubMed ID: 18485417
[TBL] [Abstract][Full Text] [Related]
29. Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin.
Cizeau J; Grenkow DM; Brown JG; Entwistle J; MacDonald GC
J Immunother; 2009; 32(6):574-84. PubMed ID: 19483652
[TBL] [Abstract][Full Text] [Related]
30. A chimeric SM5-1 antibody inhibits hepatocellular carcinoma cell growth and induces caspase-dependent apoptosis.
Dai J; Jin J; Li B; Wang H; Hou S; Qian W; Kou G; Zhang D; Li J; Tan M; Ma J; Guo Y
Cancer Lett; 2007 Dec; 258(2):208-14. PubMed ID: 17959303
[TBL] [Abstract][Full Text] [Related]
31. Synergistic antitumoral activity and induction of apoptosis by novel pan Bcl-2 proteins inhibitor apogossypolone with adriamycin in human hepatocellular carcinoma.
Mi JX; Wang GF; Wang HB; Sun XQ; Ni XY; Zhang XW; Tang JM; Yang DJ
Acta Pharmacol Sin; 2008 Dec; 29(12):1467-77. PubMed ID: 19026166
[TBL] [Abstract][Full Text] [Related]
32. [Radioimmunotherapy with 131 I-labeled humanized anti-HBsAg Fab and anti-nucleus antigen monoclonal antibody chTNT in nude mice bearing human hepatocellular carcinoma].
DU YF; Luo RC; Li GP; Li AM; Ding XM; Yan X; Huang K
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Mar; 28(3):460-2. PubMed ID: 18359714
[TBL] [Abstract][Full Text] [Related]
33. Biological characteristics of fluorescent protein-expressing human hepatocellular carcinoma xenograft model in nude mice.
Yang BW; Liang Y; Xia JL; Sun HC; Wang L; Zhang JB; Tang ZY; Liu KD; Chen J; Xue Q; Chen J; Gao DM; Wu WZ
Eur J Gastroenterol Hepatol; 2008 Nov; 20(11):1077-84. PubMed ID: 19047839
[TBL] [Abstract][Full Text] [Related]
34. STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells.
Newman SP; Foster PA; Stengel C; Day JM; Ho YT; Judde JG; Lassalle M; Prevost G; Leese MP; Potter BV; Reed MJ; Purohit A
Clin Cancer Res; 2008 Jan; 14(2):597-606. PubMed ID: 18223236
[TBL] [Abstract][Full Text] [Related]
35. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].
Song Y; Shen K; Yu JR
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2919-24. PubMed ID: 18261307
[TBL] [Abstract][Full Text] [Related]
36. Clinical evaluation of BR96 sFv-PE40 immunotoxin therapy in canine models of spontaneously occurring invasive carcinoma.
Henry CJ; Buss MS; Hellström I; Hellström KE; Brewer WG; Bryan JN; Siegall CB
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):751-5. PubMed ID: 15701865
[TBL] [Abstract][Full Text] [Related]
37. [Construction of autocatalytic caspase-3 driven by amplified human telomerase reverse transcriptase promoter and its enhanced efficacy of inducing apoptosis in human ovarian carcinoma].
Song Y; Shen K; He CX
Zhonghua Fu Chan Ke Za Zhi; 2007 Sep; 42(9):617-22. PubMed ID: 17983518
[TBL] [Abstract][Full Text] [Related]
38. Improved stability and yield of Fv targeted superantigen by introducing both linker and disulfide bond into the targeting moiety.
Hao HJ; Jiang YQ; Zheng YL; Ma R; Yu DW
Biochimie; 2005 Aug; 87(8):661-7. PubMed ID: 15927340
[TBL] [Abstract][Full Text] [Related]
39. Intratumoral anti-HuD immunotoxin therapy for small cell lung cancer and neuroblastoma.
Ehrlich D; Wang B; Lu W; Dowling P; Yuan R
J Hematol Oncol; 2014 Dec; 7():91. PubMed ID: 25523825
[TBL] [Abstract][Full Text] [Related]
40. [Effect of nobiletin on K562 cells xenograft in nude mice].
Wang Y; Su M; Yin J; Zhang H
Zhongguo Zhong Yao Za Zhi; 2009 Jun; 34(11):1410-4. PubMed ID: 19771874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
